Skip to main content
SpringerLink
Log in

Association of Prooxidant–Antioxidant Balance with Clinical and Laboratory Parameters and Its Relation to Different Drug Regimens in Polycystic Ovary Syndrome Women with Normal BMI

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Polycystic ovarian syndrome is one of the most common hormonally leading cause infertility disorders. The effect of oxidant-antioxidant imbalance on disease progression has been studied in many disorders. The present study was aimed to evaluate prooxidant–antioxidant balance (PAB) in patients with polycystic ovarian syndrome compared to healthy subjects. We also studied the possible effect of treatment with available drugs on serum PAB. In this case–control study 100 polycystic ovary syndrome (PCOS) patients and 100 healthy individuals were enrolled in the study. The laboratory features of patients and controls like as serum LH and FSH concentration and hematological examinations were collected. PAB was evaluated by a colorimetric method. Serum PAB value was significantly higher before treatment compared to after treatment and healthy subjects. PAB values were also higher in subjects with irregular menstrual cycle compared to normal subjects. Our results represented that serum PAB values has an indirect significant correlation with serum LH concentration. We also found that drugs regimen containing spironolactone effectively reduced the serum PAB values. Our results showed that PCOS patients had increased level of PAB and treatment with spironolactone mainly decreases the level of serum PAB. Our results indicate that the measurements of PAB may be used as a potential laboratory marker for assessment of PCOS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–97. doi:10.1016/S0140-6736(07)61345-2.

    Article  CAS  PubMed  Google Scholar 

  2. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51. doi:10.1093/humrep/dep399.

    Article  PubMed  Google Scholar 

  3. Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166(19):2081–6. doi:10.1001/archinte.166.19.2081.

    Article  PubMed  Google Scholar 

  4. Kuscu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009;88(5):612–7. doi:10.1080/00016340902859315.

    Article  CAS  PubMed  Google Scholar 

  5. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18(7):266–72. doi:10.1016/j.tem.2007.07.003.

    Article  CAS  PubMed  Google Scholar 

  6. San Millan JL, Alvarez-Blasco F, Luque-Ramirez M, Botella-Carretero JI, Escobar-Morreale HF. The PON1-108C/T polymorphism, and not the polycystic ovary syndrome, is an important determinant of reduced serum paraoxonase activity in premenopausal women. Hum Reprod. 2006;21(12):3157–61. doi:10.1093/humrep/del300.

    Article  CAS  PubMed  Google Scholar 

  7. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26(3):439–51. doi:10.1210/er.2005-0005.

    Article  CAS  PubMed  Google Scholar 

  8. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, Alvarez-Blasco F, Sanchon R, Luque-Ramirez M, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006;21(9):2257–65. doi:10.1093/humrep/del146.

    Article  CAS  PubMed  Google Scholar 

  9. Gonzalez F, Chang L, Horab T, Lobo RA. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Fertil Steril. 1996;66(3):354–61.

    Article  CAS  PubMed  Google Scholar 

  10. Fernandez-Real JM, Broch M, Vendrell J, Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care. 2003;26(5):1362–8.

    Article  CAS  PubMed  Google Scholar 

  11. Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;80(1):123–7. doi:10.1016/S0015-0282(03)00571-5.

    Article  PubMed  Google Scholar 

  12. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):336–40. doi:10.1210/jc.2005-1696.

    Article  CAS  PubMed  Google Scholar 

  13. Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. Pharm Ther. 2013;38(6):336–55.

    Google Scholar 

  14. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005;26(2):251–82. doi:10.1210/er.2004-0004.

    Article  CAS  PubMed  Google Scholar 

  15. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol. 2003;552(Pt 2):335–44. doi:10.1113/jphysiol.2003.049478.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lee JY, Baw C, Gupta S, Aziz N, Agarwal A. Role of oxidative stress in polycystic ovary syndrome. Curr Women’s Health Rev. 2010;6(2):96–107. doi:10.2174/157340410791321336.

    Article  CAS  Google Scholar 

  17. Gupta S, Malhotra N, Sharma D, Chandra A, Ashok A. Oxidative stress and its role in female infertility and assisted reproduction: clinical implications. Int J Fertil Steril. 2009;2(4):147–64.

    Google Scholar 

  18. Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S. The effects of oxidative stress on female reproduction: a review. Reprod Biol Endocrinol. 2012;10:49. doi:10.1186/1477-7827-10-49.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Agarwal A, Gupta S, Sharma R. Oxidative stress and its implications in female infertility—a clinician’s perspective. Reprod Biomed Online. 2005;11(5):641–50.

    Article  CAS  PubMed  Google Scholar 

  20. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25. doi:10.1016/j.fertnstert.2003.10.004.

    Article  Google Scholar 

  21. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7. doi:10.1210/jcem-21-11-1440.

    Article  CAS  PubMed  Google Scholar 

  22. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3):247–54.

    Article  CAS  PubMed  Google Scholar 

  23. Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G. A novel assay for the evaluation of the prooxidant–antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem. 2007;40(3–4):248–54. doi:10.1016/j.clinbiochem.2006.10.017.

    Article  CAS  PubMed  Google Scholar 

  24. Tavana S, Amini S, Hakhamaneshi MS, Andalibi P, Hajir MS, Ardalan A, et al. Prooxidant–antioxidant balance in patients with phenylketonuria and its correlation to biochemical and hematological parameters. J Pediatr Endocrinol Metab. 2016;. doi:10.1515/jpem-2015-0398.

    PubMed  Google Scholar 

  25. Palacio JR, Iborra A, Ulcova-Gallova Z, Badia R, Martinez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol. 2006;144(2):217–22. doi:10.1111/j.1365-2249.2006.03061.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sabuncu T, Vural H, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001;34(5):407–13. doi:10.1016/S0009-9120(01)00245-4.

    Article  CAS  PubMed  Google Scholar 

  27. Zhang D, Luo WY, Liao H, Wang CF, Sun Y. The effects of oxidative stress to PCOS. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008;39(3):421–3.

    CAS  PubMed  Google Scholar 

  28. Karadeniz M, Erdogan M, Tamsel S, Zengi A, Alper GE, Caglayan O, et al. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances. Exp Clin Endocrinol Diabetes. 2008;116(4):231–5. doi:10.1055/s-2007-992154.

    Article  CAS  PubMed  Google Scholar 

  29. Dursun P, Demirtas E, Bayrak A, Yarali H. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod. 2006;21(1):104–8. doi:10.1093/humrep/dei284.

    Article  CAS  PubMed  Google Scholar 

  30. Fenkci IV, Serteser M, Fenkci S, Kose S. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med. 2007;52(10):879–83.

    CAS  PubMed  Google Scholar 

  31. Nacul AP, Andrade CD, Schwarz P, de Bittencourt PI Jr., Spritzer PM. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol. 2007;133(2):191–6. doi:10.1016/j.ejogrb.2006.09.009.

    Article  CAS  PubMed  Google Scholar 

  32. Daneasa A, Cucolas C, Furcea M, Bolfa P, Dudea S, Olteanu D, et al. Spironolactone and dimethylsulfoxide effect on glucose metabolism and oxidative stress markers in polycystic ovarian syndrome rat model. Exp Clin Endocrinol Diabetes. 2014;122(3):154–62. doi:10.1055/s-0033-1363685.

    Article  CAS  PubMed  Google Scholar 

  33. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40(4):504–10.

    Article  CAS  PubMed  Google Scholar 

  34. Renke M, Tylicki L, Knap N, Rutkowski P, Neuwelt A, Larczynski W, et al. Spironolactone attenuates oxidative stress in patients with chronic kidney disease. Hypertension. 2008;52(5):e132–3. doi:10.1161/HYPERTENSIONAHA.108.120568 (author reply e4).

    Article  CAS  PubMed  Google Scholar 

  35. Queisser N, Happ K, Link S, Jahn D, Zimnol A, Geier A, et al. Aldosterone induces fibrosis, oxidative stress and DNA damage in livers of male rats independent of blood pressure changes. Toxicol Appl Pharmacol. 2014;280(3):399–407. doi:10.1016/j.taap.2014.08.029.

    Article  CAS  PubMed  Google Scholar 

  36. Pincemail J, Vanbelle S, Gaspard U, Collette G, Haleng J, Cheramy-Bien JP, et al. Effect of different contraceptive methods on the oxidative stress status in women aged 40 48 years from the ELAN study in the province of Liege, Belgium. Hum Reprod. 2007;22(8):2335–43. doi:10.1093/humrep/dem146.

    Article  CAS  PubMed  Google Scholar 

  37. Finco A, Belcaro G, Cesarone MR. Assessment of the activity of an oral contraceptive on the levels of oxidative stress and changes in oxidative stress after co-treatment with two different types of physiological modulators with antioxidant action. Contraception. 2011;84(4):418–22. doi:10.1016/j.contraception.2011.02.008.

    Article  CAS  PubMed  Google Scholar 

  38. Durand P, Blache D. Enhanced platelet thromboxane synthesis and reduced macrophage-dependent fibrinolytic activity related to oxidative stress in oral contraceptive-treated female rats. Atherosclerosis. 1996;121(2):205–16. doi:10.1016/0021-9150(95)05720-X.

    Article  CAS  PubMed  Google Scholar 

  39. Cai J, Cao S, Chen J, Yan F, Chen G, Dai Y. Progesterone alleviates acute brain injury via reducing apoptosis and oxidative stress in a rat experimental subarachnoid hemorrhage model. Neurosci Lett. 2015;600:238–43. doi:10.1016/j.neulet.2015.06.023.

    Article  CAS  PubMed  Google Scholar 

  40. Aksoy AN, Toker A, Celik M, Aksoy M, Halici Z, Aksoy H. The effect of progesterone on systemic inflammation and oxidative stress in the rat model of sepsis. Indian J Pharmacol. 2014;46(6):622–6. doi:10.4103/0253-7613.144922.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Ghanem H, Shaeer O, El-Segini A. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril. 2010;93(7):2232–5. doi:10.1016/j.fertnstert.2009.01.117.

    Article  CAS  PubMed  Google Scholar 

  42. Hayon T, Dvilansky A, Oriev L, Nathan I. Non-steroidal antiestrogens induce apoptosis in HL60 and MOLT3 leukemic cells; involvement of reactive oxygen radicals and protein kinase C. Anticancer Res. 1999;19(3A):2089–93.

    CAS  PubMed  Google Scholar 

  43. Anedda A, Rial E, Gonzalez-Barroso MM. Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels. J Endocrinol. 2008;199(1):33–40. doi:10.1677/JOE-08-0278.

    Article  CAS  PubMed  Google Scholar 

  44. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2011;93(1):56–62. doi:10.1016/j.diabres.2010.11.030.

    Article  CAS  PubMed  Google Scholar 

  45. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Toruner F, Cakir N, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod. 2005;20(12):3333–40. doi:10.1093/humrep/dei258.

    Article  CAS  PubMed  Google Scholar 

  46. Kocer D, Bayram F, Diri H. The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. Gynecol Endocrinol. 2014;30(5):367–71. doi:10.3109/09513590.2014.887063.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors wish to thank all patients and health stuffs who participated in this study. This work has no financially support.

Author Contribution

N. Heshmati: Data collection; S. Shahgheibi: Project development, manuscript editing; B. Nikkhoo: Data collection; S. Amini: Project development; M. Abdi: Project development data management, data analysis, manuscript writing.

Author information

Authors and Affiliations

  1. Department of Biology, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran

    Niloofar Heshmati & Sabrieh Amini

  2. Department of Gynecology and Obstetrics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Shoaleh Shahgheibi

  3. Department of Pathology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Bahram Nikkhoo

  4. Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Mohammad Abdi

  5. Department of Clinical Biochemistry, Faculty of Medicin, Kurdistan University of Medical Sciences, Sanandaj, Iran

    Mohammad Abdi

Authors
  1. Niloofar Heshmati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shoaleh Shahgheibi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bahram Nikkhoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabrieh Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammad Abdi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Abdi.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heshmati, N., Shahgheibi, S., Nikkhoo, B. et al. Association of Prooxidant–Antioxidant Balance with Clinical and Laboratory Parameters and Its Relation to Different Drug Regimens in Polycystic Ovary Syndrome Women with Normal BMI. Ind J Clin Biochem 32, 315–322 (2017). https://doi.org/10.1007/s12291-016-0613-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-016-0613-6

Keywords

Search

Navigation